
PSYCHOPHARMACOLOGY NEWSLETTER

New name: Psychopharmacology and Substance Abuse

Volume 24, Number 1

Division 28 - The American Psychological Association

Spring, 1991

PRESIDENT'S LETTER

Klaus Miczek
President, Division 28

Discovery in Psychopharmacology

"Mater artium necessitas," the old Roman proverb goes.... Or is it really luck, and not necessity, that is the true mother of invention? The shocking thing about the early discoveries in psychopharmacology for experimental researchers is their seemingly non-planned, serendipitous nature. More than two-thirds of the 30 "biggest" CNS drugs during the first decade of pharmacotherapy for affective disorders have been claimed to originate not from systematic chemical, biological and behavioral research, but from apparently lucky circumstances and so-called accidents. As a matter of fact, W. Sneader, of the University of Strathclyde in Glasgow, Scotland, stated, "In the absence of a coherent understanding of the pathological basis of a disease, only serendipity can provide effective drugs for treatment. Nowhere is this more evident than in an examination of the history of psychotherapeutic drugs." Everyone enjoys recounting the convoluted trail of discovery of chlorpromazine as a failed antihistamine, to "le cocktail psychoanalytique," to its ultimate role as an antipsychotic. How else can one account for the circuitous routes of the methyl-substituted hydrazine derivatives such as iproniazide that were first developed from the confiscated stockpiles of the V2 rocket fuels, then found to inhibit monoamine oxidase in rat and also in human brain, before they were ultimately tried as antidepressants. Psychopharmacology, more than other scientific endeavors--cynical critics maintain--seems to have been the particular beneficiary of serendipitous discoveries.

Serendipity has been a consistent theme in lectures and symposia on the early discoveries in psychopharmacology--as, for example, by the British Association of Psychopharmacology and the American College of Neuropsychopharmacology during the past few months. David Healy, in his

article "The psychopharmacological era: Notes toward a history" (1990), has argued that "...the belief that clinical advances are made through the heroic achievements of disinterested scientists is a simplistic view that may militate against future significant discoveries." But is serendipity an adequate and future-oriented explanation for the course of discovery in psychopharmacology? There are indeed serious hidden dangers in portraying psychopharmacology as an enterprise that relies chiefly on chance.

Reference to serendipitous discoveries feeds the current anti-science sentiment of a small, vocal minority. Although remarkably superior to the earlier treatment practices for affective disorders and for drug abuse, the early finds of modern psychopharmacology can only be considered as starting points for pharmacotherapies that are more conceptually and practically satisfactory. To be ready for unusual findings in the process of experimenting and investigating is indeed a necessary prerequisite characteristic of the alert and well-informed researcher who in retrospect is considered the "lucky winner." The easy and cheap findings in psychopharmacology are behind us. Affective disorders and drug abuse are complex and difficult problems escaping monocausal explanations. Multidisciplinary efforts are required to disentangle a web of interacting genetic, developmental, social, and environmental factors that render a given individual more liable to become seriously dependent on heroin or cocaine. But, how to sell complexity?

Serendipity should not be used as an excuse for failing to invest in educating future researchers in psychopharmacology. At present, tangible results for clinical application within a few years have become the yardstick by which psychopharmacological research efforts are being measured. A long string of "me-too" drugs continues to be the outcome of such a strategy. Enormous investments are required to educate young researchers who are equally well-grounded in the behavioral and biological sciences. It is this interdisciplinary perspective, however, that will engender innovation.

PROFILES OF CANDIDATES FOR DIVISION 28 OFFICE

In mid-May, you will receive a ballot asking you to vote for two Division 28 officers, President-Elect and Member-at-large. The winners of these elections will take office in August, 1991. The President-Elect will then serve as President in 1992-93 and as Past-President in 1993-94. Members-at-large, whose job is to represent the general membership at Executive Committee meetings serve for three-year terms. Profiles of the candidates are presented below.

President-Elect

LEWIS SEIDEN. Education: Ph.D. in psychology and biochemistry, University of Chicago, 1962. Research interests: relationship among monoamines, behavior, and drug action; application of computer technology to the analysis of electrophysiological and behavioral data; neuro- and psychopharmacology of antidepressant drugs and of amphetamine and related phenethylamines that have toxic effects on the central nervous system. Current position: Professor of Physiological and Pharmacological Sciences, Psychiatry, University of Chicago. Memberships: APA (Fellow, Division 28), American Association for the Advancement of Science (Fellow), American College of Neuropharmacology (Fellow), New York Academy of Sciences, Society of Biological Psychiatry, American Society for Pharmacology and Experimental Therapeutics; Service positions: NIDA, Drug Abuse Biomedical Research Review Committee; Biochemistry Research Subcommittee; NIMH, Neuropsychology Research Review Subcommittee of the Basic Psychopharmacology and Neuropsychology Research Review Committee; Merit Review Board in Neurobiology, Veterans Administration; Research Scientist Development Review Committee. Platform: 1) A primary issue is the continuing change in the field, and the need to encourage our students to become educated in recent advances in molecular biology, computer technology, etc. 2) Division 28 needs to move rapidly to form a subcommittee to study the question of clinical psychologists writing prescriptions for psychotropic drugs, so that sensible decisions regarding the long and short range role of psychologists can be made. 3) Animal regulations as spurred on by animal-welfare activists will continue to be an issue and one in which we must certainly play a key role. 4) The relationship of Division 28 to other Divisions within APA and to the APA Scientific Directorate will also be crucial in order to ensure that APA remains a viable scientific and clinical organization.

MAXINE STITZER. Education: Ph.D. in Psychopharmacology, University of Michigan, 1971. Research interests:

human behavioral pharmacology; substance abuse treatment research; development and evaluation of behavioral and pharmacological treatments for drug abuse and tobacco dependence. Current position: Associate Professor of Psychiatry and Behavioral Biology, Johns Hopkins University School of Medicine. Memberships: APA, Behavioral Pharmacology Society, Society of Behavioral Medicine. Service positions: Treasurer, APA Division 28; Grant reviewing for NIDA and other agencies; Editorial consultant: *J. Applied Behav. Anal.*, *J. Consult. Clin. Psychol.*, *Drug and Alcohol Dependence*, *Psychopharmacology*; National Academy of Science Substance Abuse Coverage Committee. Platform: The recent division name change to Psychopharmacology and Substance Abuse has emphasized our central role within APA as the substance abuse research division. More APA members, particularly those with interests in substance abuse treatment and research, need to know about us. The recent name change forms an excellent starting point for attracting new members and forming new coalitions. I would plan to work toward strengthening the representation of clinical addictions researchers within Division 28 and promoting coalitions with existing groups of clinical addictions researchers both within and outside APA. Because of my ties to the substance abuse treatment research committee, I feel I could effectively lead this initiative.

Member-at-large

JOHN GRABOWSKI. Education: Ph.D. in Psychology, University of Minnesota, 1970. Research interests: Behavioral Pharmacology: human laboratory research/antecedents and correlates of drug taking, clinical research-behavioral-pharmacological treatments for drug abuse; collateral services and treatment compliance HIV, TB; HIV and TB prevalence; Policy: drug screening, availability of therapeutic and non-therapeutic drugs, HIV screening/confidentiality, protection of human subjects. Current position: Director, Substance Abuse Research Center, University of Texas Health Science Center; Associate Professor, Psychiatry and Behavioral Sciences, UTHSC; Director, Center for the Study of Drugs in Society-Health Policy Institute, UTHSC. Appointments in School of Public Health and M.D. Anderson Center (Dept. of Cancer Prevention). Memberships: APA (fellow), APS (fellow), AABT, SBM, BPS, ABA, AAAS. Service positions: Executive Committee, Division 28, APA (1985-1991); Council of Representatives, APA (1987-1990); Chair, Task Force on Drug Abuse-Science Director, APA (1987); Chair, Task Force on Drug Abuse-Practice Director, APA (1991); Member reviewer, Clinical and Behavioral Review Committee, NIDA; ad hoc reviewer, contracts and SBIR, NIDA; ad hoc reviewer, treatment grants, OTI-ADAMHA; external reviewer, *Am. J. Pub.*

(cont. on p. 3)

Health, Am. Soc. Hosp. Pharm., Beh. Pharm., J. Clin. & Cons. Psy., Life Sci. **Platform:** The Executive Committee of Division 28 must support the activities of the diverse membership including researchers, educators/trainers, and scientist-practitioners. Division 28, through its members, must provide expertise to APA Directorates and other Divisions in the areas of psychopharmacology and substance abuse. The importance of research and the need for accuracy in portrayal and application of results must be emphasized to these consumers of data. The Division must have collaborative relations with other organizations and APA caucuses/coalitions. The Division must assure that the APA Directorates, Boards, and Council address critical issues vis-a-vis animal care, human subjects, research and training funding, substance abuse/addictive behavioral treatment and psychopharmacological education.

ALICE M. YOUNG Education: Ph.D. in Psychology, University of Minnesota, 1976. **Research interests:** Behavioral pharmacology and animal models of drug abuse: discriminative stimulus effects, behavioral and pharmacological factors in tolerance processes. **Current position:** Associate Professor of Psychology and Adjunct Associate Professor of Pharmaceutical Sciences, Wayne State University. **Memberships:** APA: Division 28 (Fellow) and Division 25, AAAS, APS (Fellow), American Society for Pharmacology and Experimental Therapeutics, Behavioral Pharmacology Society, European Behavioural Pharmacology Society, ISGIDAR, Sigma Xi, Society for Neuroscience, Society for Stimulus Properties of Drugs (SSPD). **Service positions:** APA: Program Chair, Division 28, (1982); Secretary (1983-1988); Member-at-large (1988-1991); ASPET Liaison (1988-1991); ASPET: Executive Committee, Division of Neuropharmacology (1990-1993); SSPD: Secretary-Treasurer (1989-1990), President-elect (1991); NIDA Drug Abuse Clinical and Behavioral Research Review Committee (1983-1987 and 1989-1993); Ad hoc grant reviews for NIDA and NSF; Co-organizer, 1990 International Drug Discrimination Meeting; Editorial Boards: *Pharmacology Biochemistry & Behavior*; *Behavioural Pharmacology*; Reviewer for: *Journal of Pharmacology and Experimental Therapeutics*, *Life Sciences*, *Psychopharmacology*. **Platform:** Division 28 must continue to encourage strong ties between researchers conducting basic and applied work in substance abuse and psychopharmacology. We should also continue our strong support of basic animal research, by advocacy and by providing a forum through which both basic and clinical researchers can emphasize the contributions of basic animal research to the development of effective treatments for problems of human drug abuse and psychological dysfunction. We should also continue to explore issues in graduate and post-graduate training in psychopharmacology and substance abuse.

OPEN POSITIONS

Postdoctoral Research Training in Behavioral Pharmacology:

Openings for 2 postdoctoral trainees, beginning Fall, 1991. Areas of research include: effects of psychoactive drugs on learning and memory; opioid dependence and withdrawal; discriminative stimulus effects of drugs of abuse; behavioral effects of novel analgesics; and *in vivo* applications of receptor theory. Using a variety of behavioral procedures, opioids, benzodiazepines, NMDA agonists and antagonists, and other behaviorally-active compounds are evaluated in primates and rodents. Should have completed (or nearly completed) Ph.D. in pharmacology, psychology, neuroscience, or related field. Initial appointment is for 2 years and is renewable; salary is competitive and commensurate with experience. Send letter of interest, CV, and 3 letters of recommendation to: Charles P. France, Ph.D. (504-948-8576) or Joseph M. Moerschbacher, Ph.D. (504-568-4740), Dept. of Pharmacology, Louisiana State University School of Medicine, 1901 Perdido St., New Orleans, LA 70112. LSU is an Equal Opportunity/Affirmative Action Employer.

Research Assistant Professor: Non-tenure track position available

9/1/91. Primary responsibility will be to oversee research assessing the behavioral actions of several classes of drugs. In addition, individual will teach one course a semester, either in Experimental Psychology or in Drugs and Behavior. Experience with laboratory computers is important as well as knowledge of techniques used to assess the behavioral actions of pharmacological agents. Ph.D. and some teaching and/or postdoctoral research experience required. Send letter of interest and CV before June 30, 1991 to: Dr. Linda Dykstra, Dept. of Psychology, CB# 3270, Davie Hall, University of North Carolina, Chapel Hill, NC 27599-3270. UNC-CH is an Affirmative Action/Equal Opportunity Employer.

Pre-Doctoral and Post-Doctoral Research Fellowships in Human

Behavioral Pharmacology of Drug Dependence at the University of Vermont via NIDA Institutional Training Program. Participate in the development and conduct of studies on caffeine reinforcement, pharmacological treatment of nicotine dependence, nosology of caffeine and nicotine dependence. Position is for 2-3 years. Salary ranges are competitive and adjusted according to experience. Address letter of inquiry, CV, and 3 letters of recommendation to: John R. Hughes, M.D., Human Behavioral Pharmacology Laboratory, Dept. of Psychiatry, 38 Fletcher Place/Ira Allen School, Burlington, VT, 05401 (802) 660-3065.

Post-Doctoral Positions in Drug Abuse Research.

The NIDA Addiction Research Center is the intramural research program of the National Institute on Drug Abuse. IRTA and Visiting Fellowship positions available in the Behavioral Pharmacology and Genetics Laboratory. One or more positions will be available in a recently established rhesus monkey self-administration and physical dependence laboratory. Additional positions are available to study the cardiovascular effects of abused drugs, behavioral assessment of transgenic mice, and/or biochemical changes associated with chronic drug administration. Experience with intravenous drug self-administration, drug discrimination procedures, neurochemistry, genetics, computers and/or primates (rhesus and

(cont. on p. 4)

OPEN POSITIONS (cont.)

squirrel) desirable but not essential. Duties include conducting experiments and writing manuscripts and reports. Ph.D. required, preferably in pharmacology or psychology. For the IRTA Fellowship, U.S. citizens who have less than three years of post-doctoral experience are eligible. For the Visiting Fellowship, foreign nationals with less than 3 years relevant post-doctoral experience are eligible. Salary ranges from \$25,000 to 29,000 depending on experience. The NIDA Addiction Research Center is an Equal Opportunity Employer and specifically invites and encourages applications from women, minorities, and the handicapped. If interested, please send CV and statement of interest to: Dr. Steven R. Goldberg, Chief, Behavioral Pharmacology and Genetics Laboratory, NIDA Addiction Research Center, P.O. Box 5180, Baltimore, MD 21224. The Alcohol, Drug Abuse and Mental Health Administration is an Equal Opportunity Employer. ADAMHA is smoke-free.

Assistant Director of the Behavioral Science Laboratory: Junior faculty research position (tenure-track) at the Harvard Medical School, McLean Hospital Alcohol and Drug Abuse Research Center. This is an excellent opportunity for a well-trained, productive behavioral or biological scientist (Ph.D. or M.D./Ph.D.) to collaborate in an ongoing Behavioral Science Research program and to develop independent research projects supported by extramural funding. Experience in behavioral pharmacology research (drug self-administration and drug discrimination) is essential. Responsibilities include conduct of research and supervision of pre- and post-doctoral fellows and research assistants. Macintosh computer skills are desirable. Applicants may participate in medical school teaching, but there are no formal teaching requirements. Applicants should have at least three years of post-doctoral experience and be qualified for an appointment at the Assistant Professor level. Salary commensurate with experience. The Alcohol and Drug Abuse Research Center is a broad-based basic and clinical multidisciplinary research program with a current emphasis on the behavioral pharmacology of substance abuse, the neuroendocrine consequences of cocaine and alcohol abuse, and the effects of drug abuse on the brain as assessed by brain imaging techniques (MRI, SPECT, and EEG). The Center's treatment research unit evaluates the safety and effectiveness of new pharmacotherapies. McLean Hospital is an affiliate of Harvard Medical School and Massachusetts General Hospital, located in Belmont, a Boston suburb. Send CV, reprints of at least 5 recent papers, brief statement about research interests and goals, and names of 3 references (with complete address and telephone number) to Dr. Nancy K. Mello, Prof. of Psychology (Neuroscience) and Director, Alcohol and Drug Abuse Research Center, McLean Hospital, 115 Mill St., Belmont, MA 02178. McLean is an Equal Opportunity/Affirmative Action Employer.

Research Psychologist: Ph.D. in psychology sought to support ongoing studies on the effects of stimulant, sedative, and immune-enhancing drugs on alertness, memory, and cognitive performance; and to establish other militarily-relevant research programs appropriate to the applicant's area of specialization. Preference is for background and interest in behavioral/immune system interactions, physiology of learning and memory, or human psychopharmacology. Position entails a commission

in the U.S. Army. Applicants must be U.S. citizens, in good health, under age 34. Send CV, statement of research interests, reprints, and 3 letters of recommendation to: Thomas Balkin, Ph.D., Dept. of Behavioral Biology, Division of Neuropsychiatry, Walter Reed Army Institute of Research, Washington, D.C. 20307-5100. Review of applications will begin immediately and continue until the position is filled. Women and minorities are especially encouraged to apply.

DISTINGUISHED AFFILIATE PRESENTED ABRAHAM WIKLER AWARD

Robert L. Balster
Past President, Division 28

Recently-named Division Distinguished Affiliate, Louis Harris, was presented with the Abraham Wikler Award on March 6 at the NIDA Addiction Research Center in Baltimore. The Abraham Wikler Award, in its 4th year, has been awarded to one individual each year in recognition of lifetime contributions to drug abuse research.

DIVISION MEMBERS NAMED TO APA PSYCHOPHARMACOLOGY TASK FORCE

Robert L. Balster
Past President, Division 28

Three Division 28 members, Robert Balster, Marlyne Kilbey, and Nancy Leith, were selected by the APA Board of Directors to serve on the seven-member APA Task Force on Psychopharmacology. Division member Irv Goldstein was also named a Task Force consultant. The Task Force was established by APA Council to determine the advisability and feasibility of psychopharmacology prescription privileges for psychologists, and is charged with 1) determining the competence criteria necessary for the training of psychologists to practice the highest quality patient care without adverse consequences for patients, and 2) developing and evaluating curricular models necessary to achieve these goals. Division members should direct their thoughts on these issues to members of the Task Force.

TRAVEL AWARD DEADLINE APPROACHES

The deadline for the 1991 APA Science Directorate Travel Awards is April 8, 1991. A \$300 Travel Award is given annually to 100 APA student affiliates to help pay travel expenses for graduate students who have had their research papers accepted for presentation at the Annual APA Convention. For further information call Cheri Fullerton in the Science Directorate at (202) 955-7653.

CALIFORNIA, HERE WE COME!

David M. Penetar

Program Chair, Division 28

APA's annual convention will be in San Francisco this year (August 16 - 20th), the first time since 1977. Enjoy the incredible vistas (the Marina Green at sunset as the fog swirls through the Golden Gate) and delicious food (fresh seafood with hot sour dough bread at Fisherman's Wharf) of this unique city while attending Division 28's program. This year's program features topnotch sessions on the many research interests of Division 28. Up-to-date reports on the treatment of cocaine, opiate, and nicotine abuse will be given in several symposia. The dependence potential and abuse liability of caffeine and benzodiazepines is featured in other sessions. Alcohol and the etiology of alcoholism also will be presented to round out our program to represent many of today's drug abuse problems. Not to forget our roots in the experimental analysis of behavior, two symposia are programmed featuring drug discrimination techniques and the understanding of a drug's mechanism of action. Our neuroscience interests will be seen in a symposium devoted to understanding the neurobiology of drugs of abuse and a symposium on the use of 'high tech' imaging and electrophysiology techniques to map relevant central nervous system sites of action. We are pleased to announce that our invited speakers will include James Barrett, George Bigelow, Ellen Gritz, George Koob, Joe Martinez, and Herman Samson. With the inclusion of our traditional presentations by the President (Klaus Miczek), four New Fellows, and the winner of the annual Young Psychopharmacologist Award, it will be a full schedule indeed. A complete listing of the schedule will appear in the Summer Newsletter. Abstracts will be published in *Pharmacology, Biochemistry & Behavior*, vol 39, no. 2 (June, 1991) issue.

Ride a cable car to the stars, but don't forget your sweater! As Mark Twain is reported to have said "The coldest winter was my summer in San Francisco."

SCIENCE WEEKEND, 1991

Virginia Holt

APA Science Directorate

"Science Weekend," a highly popular feature of the APA Convention for the last three years, will occur again this summer at the San Francisco meeting. From August 16-18, scientists and academics will be able to attend three solid days of "cutting edge" research presentations, with a central theme for each day's events. Twenty-two invited addresses and symposia, organized along the three themes

of "Lifespan Learning and Cognition," "Diversity," and "Scientific Basis of Psychological Interventions," are the features of the coordinated programs. At the end of each day, several Science Weekend divisions will host coordinated poster sessions/social hours. Featured speakers include:

Lifespan Learning and Cognition:

Friday, August 16

James A. Blumenthal, Duke University

Adele Diamond, University of Pennsylvania

Symposium: Research on Understanding Concepts and Representation, featuring James G. Greeno, Rogers P. Hull, Joyce L. Moore, Eric B.W. Cooper, and Richard E. Mayer

John H. Flavell, Stanford University

Robert D. Nebes, Western Psychiatric Institute and Clinic

Timothy A. Salthouse, Georgia Institute of Technology

Michael I. Posner, University of Oregon

Diversity:

Saturday, August 17

Alice Eagly, Purdue University

Robert McCrae, National Institute on Aging

Harry C. Triandis, University of Illinois

Janet E. Helms, University of Maryland

Patricia Devine, University of Wisconsin

Jerome Wiggins, University of British Columbia

Clayton Alderfer, Yale University

Jacquelyne E. Eccles, University of Colorado

Scientific Basis of Psychological Interventions:

Sunday, August 18

Symposium: Scientific Basis for Drug Abuse Treatment, featuring Travis Thompson, Robert Balster, George Bigelow, and Stephen T. Higgins

Richard I. Evans, University of Houston

Dennis Russo, New Medico Associates, Boston, Massachusetts

Elaine A. Blechman, University of Colorado

Maria R. Brassard, University of Massachusetts

Neil S. Jacobson, University of Washington

Elliot Aronson, University of California, Santa Cruz

Science Weekend is sponsored by APA's Science Directorate, Board of Scientific Affairs, and Divisions 1, 3, 5, 6, 7, 8, 12, 14, 15, 20, 21, 25, 28, 35, 38, and 47.

For further information: Virginia Holt, APA Science Directorate, 1200 17th St. NW, Washington, DC 20036; (202) 955-7653; Bitnet: APASDVEH@GWUVM.

APA PLANS HISTORIC CALENDAR FOR CENTENNIAL YEAR

Over the last two years, a database of exact dates of noteworthy events in the history of psychology has been compiled. The collection, assembled by Dr. Warren R. Street of Central Washington University, now contains over 1700 entries, gleaned from copyright records, books and articles, and correspondence with dozens of contributors.

The APA's 1992 Centennial Appointment Calendar will feature daily anniversaries of 365 of these events, accented with historic photos. Each day's space will provide plenty of room for writing reminders, appointments, and notes. You can make a luncheon date on the day the National Mental Health Act was passed (July 3), make an appointment on the day Festinger's *A Theory of Cognitive Dissonance* was published (August 27), schedule an exam on G. Stanley Hall's birthday (February 1), and raise a toast on your birthday to the memory of some event that shaped modern psychology.

A significant keepsake or a thoughtful gift, the calendar is 8" x 10", 128 pp, casebound. The cost for APA members/affiliates is \$17.95 (until September 1, 1991--\$19.95 thereafter), \$25.00 list price. Item #4500120. Available early July 1991. To reserve your copy, write to APA, Order Department, P.O. Box 2710, Hyattsville, MD 20784-0710. To order by phone using VISA or Mastercard, call (703) 247-7705 or FAX (703) 525-5081.

CORRECTION!

The article entitled "APPRECIATION FOR CORPORATE SPONSORSHIP OF DIVISION 28" on page 9 of the Winter, 1991 Newsletter incorrectly stated that the corporate sponsors listed were for 1989. The companies listed were sponsors for 1990.

LETTER TO THE EDITOR

The following letter was written in response to the article entitled "Division 28 Changes Its Name", in the Winter, 1991 Newsletter:

If we are ever to succeed with substance abuse prevention, it will be in part because we educate both the public and the profession regarding the nature of substance abuse.

In this context, it is of major concern that the phrase "drugs of abuse or alcohol" appeared in our newsletter. While I assume we all know that alcohol is the #1 drug of abuse, we misrepresent the drug and miseducate as well when we err in such writings. Both authors and editors need to be alert to assure that all references are to "alcohol and other drugs of abuse."

Andrew W. Kane, Ph.D.

Andrew W. Kane and Associates, S.C.

NAMES AND ADDRESSES: OFFICERS AND COMMITTEE CHAIRS

Nancy A. Ator, Ph.D.
Dept. of Psychiatry & Behavioral Science
Johns Hopkins School of Medicine
720 Rutland Ave., Rm. 623
Baltimore, MD 20901
(301) 955-3135

Robert L. Balster, Ph.D.
Dept. of Pharmacology & Toxicology
Medical College of Virginia
Virginia Commonwealth University
Box 613
Richmond, VA 23298
(804) 786-8402

Herbert Barry, Ph.D.
Dept. of Pharmacology
University of Pittsburgh
1110 Salk Hall
Pittsburgh, PA 15261
(412) 648-8563

Warren K. Bickel, Ph.D.
Human Behavioral Pharmacology Lab.
Dept. of Psychiatry
University of Vermont
38 Fletcher Place
Burlington, VT 05401-1195
(802) 660-3067

Larry D. Byrd, Ph.D.
Yerkes Regional Primate Research Center
Emory University
Atlanta, GA 30322
(404) 727-7730

Marilyn E. Carroll, Ph.D.
Dept. of Psychiatry
University of Minnesota
Box 392 UMHC
Minneapolis, MN 55455
(612) 626-6289

Hugh L. Evans, Ph.D.
Institute of Environmental Medicine
New York University Medical Center
550 First Av.
New York, NY 10016
(914) 351-4249

Stephen C. Fowler, Ph.D.
Dept. of Psychology
University of Mississippi
Peabody Hall, Room 301
University, MS 38677
(601) 232-7383

John G. Grabowski, Ph.D.
Dept. of Psychiatry & Behavioral Science
University of Texas
1300 Moursund
Houston, TX 77030
(713) 792-7925

Jack E. Henningfield, Ph.D.
National Institute on Drug Abuse
Addiction Research Center
P.O. Box 5180
Baltimore, MD 21224
(301) 550-1494

Stephen T. Higgins, Ph.D.
Human Behavioral Pharmacology Lab.
Univ. of VT Dept. of Psychiatry
38 Fletcher Place
Burlington, VT 05401
(802) 660-3066

Chris Ellyn Johanson, Ph.D.
Uniformed Services University of Health Sciences
4301 Jones Bridge Rd.
Bethesda, MD 20814
(301) 295-3470

M. Marlyne Kilbey, Ph.D.
Dept. of Psychology
Wayne State University
71 W. Warren
Detroit, MI 48207
(313) 577-2802

Klaus Miczek, Ph.D.
Dept. of Psychology
Tufts University
490 Boston Av.
Medford, MA 02155
(617) 381-3414

Donald A. Overton, Ph.D.
Depts. of Psychology and Psychiatry
Temple University
Weiss Hall
Philadelphia, PA 19122
(215) 787-1534

David M. Penetar, Ph.D.
Dept. of Behavioral Biology
Walter Reed Army Institute of Research
Washington, DC 20307-5100
(301) 427-5521

Cynthia S. Pomerleau, Ph.D.
Behavioral Medicine Program
Univ. of MI Dept. of Psychiatry
900 Wall St.
Ann Arbor, MI 48105
(313) 764-7152

Robert L. Sprague, Ph.D.
Institute for Child Behavior & Development
University of Illinois
51 Gerty Dr.
Champaign, IL 61820
(217) 333-4123

Ronald W. Wood, Ph.D.
Institute of Environmental Medicine
New York University Medical Center
550 First Av.
New York, NY 10016
(914) 351-4249

Alice M. Young, Ph.D.
Dept. of Psychology, Wayne State University
71 W. Warren Av.
Detroit, MI 48202
(313) 577-3290

DIVISION 28 OFFICERS:		Term	Newsletter Editor	Cynthia S. Pomerleau	5/88-8/91
<i>Elected:</i>					
President	Klaus Miczek (617) 381-3414	8/89-8/92	Membership Chair	Stephen C. Fowler (601) 232-7383	8/88-8/91
President-Elect	Ronald W. Wood (914) 351-4249	8/90-8/93	CPDD Liaison	Robert L. Balster (804) 786-8402	
Past-President	Robert L. Balster (804) 786-8402	9/88-8/91	Public Information	John G. Grabowski (713) 792-7925	6/87-8/91
Council Representative	Stephen C. Fowler (601) 232-7383	2/91-1/94	ASPET Liaison Officers	Alice M. Young (313) 577-3290	9/89-8/91
Members-at-large	Alice M. Young (313) 577-3290	9/88-8/91	APA Public Affairs Liaison	Chris Johanson (301) 295-3470	8/89-9/91
	Robert Sprague (217) 333-4123	8/89-8/92	APS Liaison	Donald Overton (215) 787-1534	8/89-9/91
	Marilyn E. Carroll (612) 626-6289	8/90-8/93	Committee on Nominations	Larry D. Byrd (404) 727-7730	8/89-8/91
<i>Appointed:</i>					
Treasurer	Jack E. Henningfield (301) 550-1494	8/88-8/91	Neurobehavioral Tox. Committee	Ronald W. Wood (914) 351-4249	8/89-8/91
Secretary	Stephen T. Higgins (802) 660-3066	8/88-8/91	Committee on Animal Research	Hugh L. Evans (914) 351-4249	8/89-8/91
Program Chair, 1991	David Penetar (301) 427-5521	8/89-8/92	Committee on Prescript. Priv.	Marlyne Kilbey (313) 577-2802	8/89-8/91
Past-Program Chair	Warren K. Bickel (802) 660-3067	9/88-8/91	Centennial Officer	Herbert Barry (412) 648-8563	8/89-8/91
Incoming Program Chair	Nancy Aton (301) 955-3135	8/90-8/93			

NEWSLETTER DEADLINES (Newsletter appears 4-6 weeks later):

Fall issue: September 15 Spring Issue: March 15
 Winter issue: December 15 Summer Issue: June 15

Cynthia S. Pomerleau, Ph.D.
 Editor, *Division 28 Newsletter*
 Behavioral Medicine Program
 University of Michigan Department of Psychiatry
 Riverview Building, 900 Wall Street
 Ann Arbor, MI 48105



000010444951 F CS0 2613
 DR VICTOR G LATIES
 SCH OF MED
 UNIV OF ROCHESTER BOX EHSC
 ROCHESTER NY 14642

